National Heart, Lung, and Blood Institute; Notice of Closed Meetings, 46493-46494 [06-6875]
Download as PDF
Federal Register / Vol. 71, No. 156 / Monday, August 14, 2006 / Notices
Dated: August 1, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E6–13191 Filed 8–11–06; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
Federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
jlentini on PROD1PC65 with NOTICES
SUMMARY:
Adoptive T-Cell Transfer After
Lymphodepletion Promotes Tumor
Regression
Description of Technology: Available
for licensing is a method of adoptive
cell transfer (ACT) immunotherapy.
Since its first description, ACT is now
being developed for the supportive
treatment of a variety of infectious
diseases and cancer.
Current ACT methods to treat cancer
are based on the ex vivo selection of
lymphocytes with high avidity for
recognition of tumor antigens, and their
activation and numerical expansion
before re-infusion to the autologous
tumor-bearing host. The current
invention improves ACT by including a
pre-treatment regimen to ensure
permissive conditions in the host for in
vivo proliferation of the transferred
cells. Specifically, the immune system
is suppressed by pre-treatment with
lymphodepleting chemotherapy. Two
VerDate Aug<31>2005
04:45 Aug 12, 2006
Jkt 208001
separate clinical trials have
demonstrated that using this approach,
ACT can induce lasting tumor
shrinkage.
Lymphodepleting chemotherapy
followed by ACT resulted in tumor
shrinkage of at least 50 percent in 6 out
of 13 treated patients suffering from
refractory melanoma. Several patients
remained cancer free for more than a
year after treatment. The usefulness of
combined ACT and lymphodepleting
therapy for cancer treatment was
confirmed when this study was
extended to include 35 melanoma
patients. Eighteen of the 35 patients
(51%) responded to the treatment,
including 3 patients who experienced
ongoing complete disappearance of
cancer and 15 patients had tumor
shrinkage of at least 50 percent with a
mean duration of almost a year after
treatment. In a recent clinical trial that
is not yet published, using a modified
protocol to treat 23 patients, a similar
response rate (56%) was seen.
This approach to ACT offers a
potentially significant improvement in
the treatment of many types of cancer.
In addition, this method might be
applicable in treating other diseases
such as AIDS, immunodeficiency, or
other autoimmunity for which immune
effector cells can impact the clinical
outcome.
Inventors: Mark E. Dudley, Steven A.
Rosenberg, John R. Wunderlich (NCI)
Publications:
1 . Dudley ME, et al. ‘‘Adoptive cell
transfer therapy following nonmyeloablative but lymphodepleting
chemotherapy for the treatment of
patients with refractory metastatic
melanoma.’’ J Clin Oncol. 2005 Apr
1;23(10):2346–2357.
2 . Dudley ME, et al. ‘‘Cancer
regression and autoimmunity in patients
after clonal repopulation with antitumor
lymphocytes.’’ Science. 2002 Oct
25;298(5594):850–854.
Patent Status: U.S. Provisional
Application No. 60/408,681 filed 06 Sep
2002 (HHS Reference No. E–275–2002/
0–US–01) PCT Application No. PCT/
US03/27873 filed 05 Sep 2003, which
published as WO 2004/021995 on 18
Mar 2004 (HHS Reference No. E–275–
2002/1–PCT–01)
U.S. Patent Application No. 10/
526,697 filed 05 May 2005 (HHS
Reference No. E–275–2002/1–US–02)
Licensing Status: Available for
exclusive and non-exclusive licensing.
Licensing Contact: Michelle A.
Booden, Ph.D.; 301/451–7337;
boodenm@mail.nih.gov
Collaborative Research Opportunity:
The NCI Surgery Branch is seeking
statements of capability or interest from
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
46493
parties interested in collaborative
research to further develop, evaluate, or
commercialize ACT therapy. Please
contact Steven A. Rosenberg, M.D.,
Ph.D. at 301–496–4164 for more
information.
Dated: August 3, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E6–13193 Filed 8–11–06; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
Pursuant to Section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute, Special Emphasis Panel,
Cardiovascular Cell Therapy Research
Network Review.
Date: August 14–15, 2006.
Time: 8 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott, 5151 Pooks Hill
Road, Bethesda, MD 20814.
Contact Person: David A. Wilson, PhD,
Scientific Review Administrator, Review
Branch, Division of Extramural Affairs,
National Heart, Lung, and Blood Institute,
National Institutes of Health, 6701 Rockledge
Drive, Room 7204, MSC 7924, Bethesda, MD
20892, 301/435–0929,
wilsond@nhlbi.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Heart, Lung,
and Blood Institute, Special Emphasis Panel,
Minority Undergraduation Biomedical
Education.
Date: August 16, 2006.
Time: 9 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\14AUN1.SGM
14AUN1
jlentini on PROD1PC65 with NOTICES
46494
Federal Register / Vol. 71, No. 156 / Monday, August 14, 2006 / Notices
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Roy L. White, PhD,
Scientific Review Administrator, Division of
Extramural Affairs, Review Branch, National
Heart, Lung, and Blood Institute, NIH, 6701
Rockledge Drive, Rm. 7202, Bethesda, MD
20892–7924, 301/435–0310,
whiterl@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Heart, Lung,
and Blood Institute, Special Emphasis Panel,
Atherosclerosis in a Swine Model.
Date: August 23, 2006.
Time: 1 p.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Katherine M. Malinda,
PhD, Scientific Review Administrator,
Review Branch, Division of Extramural
Affairs, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7198,
Bethesda, MD 20892, (301) 435–0297,
malindak@nhlbi.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Heart, Lung,
and Blood Institute, Special Emphasis Panel,
Shared Resource Grant Application Review.
Date: August 25, 2006.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Sheiley S. Sehnert, PhD,
Scientific Review Administrator, Review
Branch, NIH/NHLBI, 6701 Rockledge Drive,
Room 7206, Bethesda, MD 20892–7924, 301/
435–0303, ssehnert@nhlbi.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel,
Lung Biology Program Project.
Date: August 31, 2006.
Time: 2 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge Center Two, 6701 Rockledge
Drive, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Keith A. Mintzer, PhD,
Scientific Review Administrator, Division of
Extramural Affairs, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6701 Rockledge Drive, Room 7186, NSC
7924, Bethesda, MD 20892, 301–435–0280,
mintzerk@nhlbi.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
VerDate Aug<31>2005
17:58 Aug 11, 2006
Jkt 208001
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: August 7, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–6875 Filed 8–11–06; 8:45 am]
BILLING CODE 4140–01–M
Bioengineering, 6701 Democracy Blvd, Room
241, Bethesda, MD 20892.
Information is also available on the
Institute’s/Center’s home page: https://
www.nibib1.nih.gov/about/NACBIB/
NACBIB.htm, where an agenda and any
additional information for the meeting
will be posted when available.
Dated: August 7, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–6876 Filed 8–11–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Environmental
Health Sciences; Notice of Closed
Meeting
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
National Advisory Committee for
Biomedical Imaging and Bioengineering.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed blow in
advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended.
The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council or Biomedical Imaging and
Bioengineering.
Date: September 15, 2006.
Time: 8 a.m. to 5 p.m.
Agenda: Grant applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Anthony Demsey, PhD,
Director, Office of Extramural Policy,
National Institute of Biomedical Imaging and
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel.
Date: August 31, 2006.
Time: 10 a.m. to 1 p.m.
Agenda: To review and evaluate contract
proposals.
Place: NIEHS/National Institutes of Health,
Building 4401, East Campus, 79 T.W.
Alexander Drive, 122, Research Triangle
Park, NC 27709.
Contact Person: Michelle Victalino,
Scientific Review Branch, Division of
Extramural Research and Training, Nat’l
Institute of Environmental Health Sciences,
P.O. Box 12233, MD EC–30, Research
Triangle Park, NC 27709, 919/541–3035,
victoalinom@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk
Estimation—Health Risks from
Environmental Exposures; 93.142, NIEHS
Hazardous Waste Worker Health and Safety
Training; 93.143, NIEHS Superfund
Hazardous Substances—Basic Research and
Education; 93.894, Resources and Manpower
Development in the Environmental Health
Sciences; 93.113, Biological Response to
E:\FR\FM\14AUN1.SGM
14AUN1
Agencies
[Federal Register Volume 71, Number 156 (Monday, August 14, 2006)]
[Notices]
[Pages 46493-46494]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-6875]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meetings
Pursuant to Section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute,
Special Emphasis Panel, Cardiovascular Cell Therapy Research Network
Review.
Date: August 14-15, 2006.
Time: 8 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD
20814.
Contact Person: David A. Wilson, PhD, Scientific Review
Administrator, Review Branch, Division of Extramural Affairs,
National Heart, Lung, and Blood Institute, National Institutes of
Health, 6701 Rockledge Drive, Room 7204, MSC 7924, Bethesda, MD
20892, 301/435-0929, wilsond@nhlbi.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Heart, Lung, and Blood Institute,
Special Emphasis Panel, Minority Undergraduation Biomedical
Education.
Date: August 16, 2006.
Time: 9 a.m. to 12 p.m.
Agenda: To review and evaluate grant applications.
[[Page 46494]]
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Roy L. White, PhD, Scientific Review
Administrator, Division of Extramural Affairs, Review Branch,
National Heart, Lung, and Blood Institute, NIH, 6701 Rockledge
Drive, Rm. 7202, Bethesda, MD 20892-7924, 301/435-0310,
whiterl@mail.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Heart, Lung, and Blood Institute,
Special Emphasis Panel, Atherosclerosis in a Swine Model.
Date: August 23, 2006.
Time: 1 p.m. to 2 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Katherine M. Malinda, PhD, Scientific Review
Administrator, Review Branch, Division of Extramural Affairs,
National Heart, Lung, and Blood Institute, 6701 Rockledge Drive,
Room 7198, Bethesda, MD 20892, (301) 435-0297,
malindak@nhlbi.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Heart, Lung, and Blood Institute,
Special Emphasis Panel, Shared Resource Grant Application Review.
Date: August 25, 2006.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Sheiley S. Sehnert, PhD, Scientific Review
Administrator, Review Branch, NIH/NHLBI, 6701 Rockledge Drive, Room
7206, Bethesda, MD 20892-7924, 301/435-0303, ssehnert@nhlbi.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel, Lung Biology Program Project.
Date: August 31, 2006.
Time: 2 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge Center Two, 6701
Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Keith A. Mintzer, PhD, Scientific Review
Administrator, Division of Extramural Affairs, National Heart, Lung,
and Blood Institute, National Institutes of Health, 6701 Rockledge
Drive, Room 7186, NSC 7924, Bethesda, MD 20892, 301-435-0280,
mintzerk@nhlbi.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: August 7, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 06-6875 Filed 8-11-06; 8:45 am]
BILLING CODE 4140-01-M